Accelerate Diagnostics, Inc.

The company provides diagnostic solutions for serious infections in US, Europe, and Middle East. It offers the Accelerate Pheno system for identifying pathogens and antibiotic susceptibility testing. The platform targets gram-positive and gram-negative organisms associated with serious infections. The company also provides the Accelerate PhenoTest kit for identity and antibiotic susceptibility testing. This test is used to diagnose bacteremia or fungemia, life-threatening conditions. The company was formerly known as Accelr8 Technology Corporation before changing its name in 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Overview

Sector

Medical Devices

Target Price

0.0 USD

Current Price

0.0 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (13.90).
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (2.97%).
EV/EBIT (100.00) is significantly higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0